PD-1

[Cell Reports Medicine] Investigators demonstrated that AXL was a critical targetable driver of immune suppression in STK11/LKB1 mutant NSCLC.

[Imugene] Merck announced that it will stop the Phase II KEYLYNK-010 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with LYNPARZA, a PARP inhibitor, for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide.

[Cell Reports] Scientists reported that tumor-derived Jagged1 is a key regulator of the tumor immune microenvironment. Jagged1 promoted tumorigenesis in multiple spontaneous mammary tumor models.

[Immunity] Although PD-1 and TIGIT are thought to regulate different costimulatory receptors, effectiveness of PD-1 or TIGIT inhibition in preclinical tumor models was reduced in the absence of CD226.

[Clinical Cancer Research] Researchers investigated the combination of IL-15 with an intratumoral anti-CD40 monoclonal antibody (mAb) in a dual tumor TRAMP-C2 murine prostate cancer model and expanded the regimen to include an anti-PD-1 mAb.

[Journal of Hepatology] Scientists identified a proinflammatory hepatocyte subpopulation that developed primarily from periportal hepatocytes and to a lesser extent from pericentral hepatocytes and played key immunoregulatory roles in endotoxemia.